Ask Bio: AAV2 GDNF Trials for Parkinson's (Rallying 2024)

Rallying to the Challenge 2024 - Day 2
Dr Alan Whone, University of Bristol
Dr Alan Whone from the University of Bristol discusses the set-up and results from the phase 1b trial of GDNF - a neurotrophic factor - for Parkinson's, as well as the upcoming phase 2 trial of the same therapy, titled "REGENERATE PD". The therapy is created by the pharmaceutical company AskBio and differs from previous GDNF trials as it uses gene therapy approach to administer GDNF.
REGENERATE PD will be recruiting participants in the US and UK. If you are interested in participating, please speak to your neurologist, review the information on clinicaltrials.gov/study/NCT06285643 or foxtrialfinder.michaeljfox.org, and/or email AskBio at [e-mail].
This talk was given as a part of the Rallying to the Challenge meeting, hosted by Cure Parkinson's and the Van Andel Institute in Grand Rapids, Michigan on September 23-24, 2024. Rallying to the Challenge is a meeting designed for and by people with Parkinson’s, advocates, and care partners to explore how the Parkinson’s community can impact and accelerate research. It is a part of the larger Grand Challenges in Parkinson's Disease meeting, an annual scientific symposium for Parkinson's research.

[@gisellakneen]

I would like to be entered into this trial but I’m not sure if I’m gonna be allowed to as I have been diagnosed with Parkinsonism scans have shown a deficiency of dopamine producing cells in the right side basal ganglia compared to the left. My ability to move my lower body is deteriorating really quickly so I am anxious to try anything that might arrest the deterioration

[@RickinICT]

Regenerate PD Study
Professor Alan Whone
University of Bristol
AB-1005 Gene Therapy
GDNF
(for anyone trying to find this video via search, since there's no video description added.)